It has been previously shown that CRCs carrying KRAS and P53 mutations remain strictly dependent on APC loss (Dow et al., 2015), indicating that the WNT signaling pathway is an important therapeutic target for treatment of CRC. Here, KRAS is linked to colorectal carcinoma.